Aphase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma

Don M. Benson, Craig C. Hofmeister, Swaminathan Padmanabhan, Attaya Suvannasankha, Sundar Jagannath, Rafat Abonour, Courtney Bakan, Pascale Andre, Yvonne Efebera, Jérôme Tiollier, Michael A. Caligiuri, Sherif S. Farag

Research output: Contribution to journalArticle

147 Scopus citations

Abstract

Natural killer (NK) cells elicit cytotoxicity against multiple myeloma (MM); however, MM cells express HLA class I molecules as ligands to NK cell inhibitory killer immunoglobulin-like receptors (KIRs) as a means of immunoevasion. KIR-ligand mismatch may improve outcomes in allogeneic transplantation for MM. Extrapolating on this concept, we conducted a phase 1 trial of IPH2101, an anti-KIR antibody, in patients with relapsed/refractory MM. IPH2101 was administered intravenously every 28 days in 7 dose-escalated cohorts (0.0003-3 mg/kg) for up to 4 cycles. Pharmacokinetic, pharmacodynamic, and correlative immunologic studies were completed. A total of 32 patients were enrolled. The biologic endpoint of full KIR2D occupancy across the dosing cycle was achieved without dose-limiting toxicity or maximally tolerated dose. One severe adverse event was noted. Pharmacokinetic and pharmacodynamic findings approximated preclinical predictions, and IPH2101 enhanced ex vivo patient-derived NK cell cytotoxicity against MM. No objective responses were seen. No evidence of autoimmunity was observed. These findings suggest that IPH2101 is safe and tolerable at doses that achieve full inhibitory KIR saturation, and this approach warrants further development in MM. This trial was registered at www.clinicaltrials.gov as #NCT00552396.

Original languageEnglish (US)
Pages (from-to)4324-4333
Number of pages10
JournalBlood
Volume120
Issue number22
DOIs
StatePublished - Nov 22 2012

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'Aphase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma'. Together they form a unique fingerprint.

  • Cite this

    Benson, D. M., Hofmeister, C. C., Padmanabhan, S., Suvannasankha, A., Jagannath, S., Abonour, R., Bakan, C., Andre, P., Efebera, Y., Tiollier, J., Caligiuri, M. A., & Farag, S. S. (2012). Aphase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood, 120(22), 4324-4333. https://doi.org/10.1182/blood-2012-06-438028